Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 28 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Durvalumab (Imfinzi) for locally advanced or metastatic urothelial bladder cancer – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Bladder cancer	Urological Cancer	2017	View \| Download
Durvalumab (Imfinzi) monotherapy for advanced or metastatic non-small cell lung cancer (EGFR and ALK wild type) – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Durvalumab add-on therapy for previously untreated locally advanced cervical cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Cervical cancer	Female Reproductive Cancer	2022	View \| Download
Durvalumab adjuvant therapy for treating hepatocellular carcinoma at high risk of recurrence after curative treatment	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Durvalumab and bevacizumab in addition to transarterial chemoembolisation for locoregional hepatocellular carcinoma	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Durvalumab and enfortumab vedotin with or without tremelimumab for muscle-invasive bladder cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Enfortumab vedotin (ASG-22ME; Padcev) , Tremelimumab (CP-675206; CP-675 206)	Bladder cancer	Urological Cancer	2024	View \| Download
Durvalumab for advanced, EGFR/ALK wild-type, high PD-L1 expression, non-small cell lung cancer- first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Durvalumab for limited stage small-cell lung cancer after 1 therapy	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2022	View \| Download
Durvalumab for previously untreated,hepatocellular carcinoma	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Durvalumab for recurrent or metastatic squamous cell carcinoma of the head and neck – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Head and neck cancer	Head and Neck Cancer	2019	View \| Download